Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript

May 25, 2022 / 04:15PM GMT
Release Date Price: €31.38 (-5.64%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Good afternoon, everyone. I'm Ellie Merle. Thank you so much for joining us at the UBS Global Healthcare Conference in person. Very happy to have Arrowhead Pharmaceuticals here with us for a fireside chat today. Joining us from Arrowhead is Vince Anzalone, VP, Finance and Investor Relations; and Dr. James Hamilton, the Head of Discovery and Translational Research. Thank you very much for joining us.

Questions & Answers

Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Maybe to kick it off before we go into some of the specific programs high level, you guys have an exciting RNAi platform with a lot of potential applications. Can you frame for us where do you see the strategy from a prioritization perspective and where you see the company and the platform evolving over the next, say, 3, 5 years?

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Sure. And I want to start by saying thanks to Ellie

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot